Using a special antibody to target brain cancer cells
Targeting Glioblastoma with a Nuclear-penetrating Anti-DNA Autoantibody
This study is looking at a new way to treat glioblastoma, a tough brain cancer, by using a special antibody that can reach the brain and target cancer cells without hurting healthy ones, with the hope of making treatments work better for patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Yale University NIH-funded |
| Lab location | 1 site (New Haven, United States) |
| Project ID | NIH-10770985 on NIH RePORTER |
What this research studies
This research focuses on glioblastoma multiforme (GBM), a highly aggressive brain cancer that often recurs despite treatment. The study explores a novel approach using an anti-DNA autoantibody, which can penetrate the blood-brain barrier and selectively target cancer cells with specific genetic defects. By re-engineering this antibody, researchers aim to enhance its effectiveness against GBM while minimizing harm to normal cells. The goal is to improve treatment outcomes for patients with this challenging condition.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with glioblastoma multiforme, particularly those with PTEN-deficient tumors.
Not a fit: Patients with glioblastoma who do not have PTEN deficiencies or those with other types of brain tumors may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for glioblastoma, potentially improving survival rates and quality of life for patients.
How similar studies have performed: Other research has shown promise in using antibodies to target cancer cells, suggesting that this approach could be effective, though the specific use of this antibody in GBM is relatively novel.
Where this research is happening
New Haven, United States
- Yale University — New Haven, United States (Active)
Researchers
- Principal investigator: Hansen, James E. — Yale University
- Study coordinator: Hansen, James E.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.